试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-28
Improving Function,Welfare of Late-stage Cancer Subjects by ACC
编号:NCT03057314登记状态:提前终止企业 / 申办者:Amorphical Ltd.
药物 / 成分:Amorphous Calcium Carbonate
登记的停止原因(原文):Slow recreuitment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-28
Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans
编号:NCT03179163登记状态:提前终止企业 / 申办者:Penn State University
药物 / 成分:Captopril Pill、Enalapril Pill、Hydrochlorothiazide
登记的停止原因(原文):COVID shut down human subjects research and then the grant funding expired
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-28
Pembrolizumab + Idelalisib for Lung Cancer Study
编号:NCT03257722登记状态:提前终止企业 / 申办者:Asha Nayak
药物 / 成分:Pembrolizumab、Idelalisib
登记的停止原因(原文):The study was terminated due to poor accrual.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-28
Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer
编号:NCT03370198登记状态:提前终止企业 / 申办者:Celyad Oncology SA
药物 / 成分:NKR-2 cells
登记的停止原因(原文):Difficulties in patient recruitment and clinical strategy modification based on new clinical data generated in the NKR-2 early development.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-28
The Effect of Amorphous Calcium Carbonate (ACC) Treatment on Function and Welfare in Late-stage Solid Cancer Subjects
编号:NCT03582280登记状态:提前终止企业 / 申办者:Amorphical Ltd.
药物 / 成分:Amorphous Calcium Carbonate (ACC) - Amor
登记的停止原因(原文):Slow recruitment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-28
Cerebrovascular Reactivity Assessed With fNIRS as a Biomarker of TCVI After Acute Traumatic Brain Injury in Military
编号:NCT04058132登记状态:提前终止企业 / 申办者:Uniformed Services University of the Health Sciences
药物 / 成分:Sildenafil Citrate 50Mg Tab、functional Near-infrared Spectroscopy (fNIRS)、Carbon Dioxide (CO2) 5%、Neuropsychological Assessments
登记的停止原因(原文):funding ran out after unanticipated length of time ( for IRB approval, CRADA, and start letter
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-28
FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy
编号:NCT04491084登记状态:提前终止企业 / 申办者:Albert Einstein College of Medicine
药物 / 成分:FLT3 Ligand (CDX-301)、anti-CD40 antibody (CDX-1140)、SBRT
登记的停止原因(原文):Low accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-28
Intraoperative Methadone in Children Undergoing Surgery
编号:NCT04680286登记状态:提前终止企业 / 申办者:University of Aarhus
药物 / 成分:Methadone Hydrochloride、Placebo
登记的停止原因(原文):Slow recruitment due to covid-19 and organizational changes.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-28
Efficacy and Safety of Hemorrane Plus Versus Hemorrane and Versus Placebo in Patients With Uncomplicated Haemorrhoids
编号:NCT05788497登记状态:提前终止企业 / 申办者:Faes Farma, S.A.
药物 / 成分:Hemorrane plus、Hemorrane、Placebo
登记的停止原因(原文):Recruitment failure
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-26
Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis
编号:NCT03169894登记状态:提前终止企业 / 申办者:Avalo Therapeutics, Inc.
药物 / 成分:MDGN-002
登记的停止原因(原文):Strategic reasons
查看官方原始记录 ↗